Equillium Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer
Equillium, Inc. (EQ)
Last equillium, inc. earnings: 3/26 04:07 pm
Check Earnings Report
Company Research
Source: Business Wire
Combination of IL-15 and IL-21 robustly augments NK and CD8 T cell activity LA JOLLA, Calif.--(BUSINESS WIRE)--Equillium Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that an abstract was accepted for poster presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer. The conference will take place at the George R. Brown Convention Center in Houston, Texas from November 6 to 10, 2024.Title: Interleukin (IL)-15 and IL-21 synergistically enhance NK and CD8+ T cell responsesPresenting Author: Phoi Tiet, Senior Research Associate, Equillium, Inc.Abstract Number: 908Location: Exhibit Halls A & BDate: Saturday, November 9, 2024The abstract highlights that cytokines are a focus of anti-cancer therapeutic development due to their central role in regulating anti-tumoral immune responses, and that data demonst
Show less
Read more
Impact Snapshot
Event Time:
EQ
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EQ alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EQ alerts
High impacting Equillium, Inc. news events
Weekly update
A roundup of the hottest topics
EQ
News
- Graft versus Host Disease Market to Increase at a CAGR of 9.9% During the Study Period (2020–2034) | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Equillium collaborates with Vivtex for oral formulation of autoimmune therapy [Yahoo! Finance]Yahoo! Finance
- Equillium to Present at the Stifel Virtual Inflammation & Immunology SummitBusiness Wire
- Equillium Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Equillium to Present at the Wells Fargo Healthcare Conference and the H.C. Wainwright 26th Annual Global Investor ConferenceBusiness Wire
EQ
Earnings
- 5/9/24 - Beat
EQ
Analyst Actions
- 8/19/24 - HC Wainwright
EQ
Sec Filings
- 9/27/24 - Form 4
- 9/17/24 - Form 4
- 8/8/24 - Form 10-Q
- EQ's page on the SEC website